Anna V. Tinker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna V. Tinker has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Martin Köbel
Department of Pathology and Laboratory Medicine, University of Calgary
8 shared publications - Mansoor Raza Mirza
Rigshospitalet, Copenhagen University Hospital , Copenhagen
7 shared publications - Adriano Gravina
Clinical Trial Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples
6 shared publications - Ana Oaknin
Vall d’Hebron Institute of Oncology (VHIO) 7 Medical Oncology Service, Vall d’Hebron Barcelona Hospital Campus, Instituto de Investigación Sanitaria Hospital Universitari Vall d’Hebron (IIS IR-HUVH) Barcelona, Spain
6 shared publications - Bhavana Pothuri
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New York University Grossman School of Medicine, United States
6 shared publications - Cara Mathews
Program in Women's Oncology, Women & Infants Hospital, Legorreta Cancer Center at Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI, USA
6 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 330
Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer
Background: Folate receptor alpha (FRα), commonly expressed in epithelial ovarian cancers, is a clinically actionable biomarker following approval of the antibody–drug conjugate mirvetuximab soravtansine (MIRV). Pivotal trials showed that high FRα expression predicts MIRV benefit, creating the need for standardized testing to ensure timely, equitable access. Methods: To address the need for guidance on FRα testing, the Society of Gynecologic Oncology of Canada convened a multidisciplinary Expert Panel to review the evidence and integrate Canadian clinical, pathology, laboratory, and patient perspectives. Consensus recommendations were developed through structured evidence review, expert discussion, iterative revision, and patient partner input. Results: The panel issued recommendations on the clinical role and timing of FRα testing, tissue requirements, assay selection and validation, interpretation and reporting standards, laboratory quality assurance, reimbursement, and equitable access. It is recommended that FRα testing be available to all patients with epithelial ovarian cancer, with results available no later than platinum-resistant disease, using a validated assay, preferably the Ventana FOLR1 RxDx assay or an appropriately validated laboratory-developed test. Standardized synoptic reporting, participation in external quality assurance programs, and clear patient communication were deemed essential. Conclusions: These recommendations aim to promote integrated, equitable, standardized FRα testing across Canada and support timely identification of patients eligible for FRα-directed therapy, clinical trial enrollment, and future biomarker-driven treatment strategies.
- 1 June 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 330
Open AccessConsensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer
Background: Folate receptor alpha (FRα), commonly expressed in epithelial ovarian cancers, is a clinically actionable biomarker following approval of the antibody–drug conjugate mirvetuximab soravtansine (MIRV). Pivotal trials showed that high FRα expression predicts MIRV benefit, creating the need for standardized testing to ensure timely, equitable access. Methods: To address the need for guidance on FRα testing, the Society of Gynecologic Oncology of Canada convened a multidisciplinary Expert Panel to review the evidence and integrate Canadian clinical, pathology, laboratory, and patient perspectives. Consensus recommendations were developed through structured evidence review, expert discussion, iterative revision, and patient partner input. Results: The panel issued recommendations on the clinical role and timing of FRα testing, tissue requirements, assay selection and validation, interpretation and reporting standards, laboratory quality assurance, reimbursement, and equitable access. It is recommended that FRα testing be available to all patients with epithelial ovarian cancer, with results available no later than platinum-resistant disease, using a validated assay, preferably the Ventana FOLR1 RxDx assay or an appropriately validated laboratory-developed test. Standardized synoptic reporting, participation in external quality assurance programs, and clear patient communication were deemed essential. Conclusions: These recommendations aim to promote integrated, equitable, standardized FRα testing across Canada and support timely identification of patients eligible for FRα-directed therapy, clinical trial enrollment, and future biomarker-driven treatment strategies.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 10 October 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (1) , 102719
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
- 10 October 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (1) , 102719
Open AccessIdentifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
- Open Access
- 9 October 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (12) , 102709
Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer
- 9 October 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (12) , 102709
Open AccessBridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer
- Open Access
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan
Background: The initial response to coronavirus disease 2019 (COVID-19) in Ontario included suspension of cancer screening programs and deferral of diagnostic procedures and many treatments. Although the short-term impact of these measures on female cancers is well documented, few studies have assessed the mid- to long-term impacts. Objectives: To compare annual billing prevalence and incidence rates of female cancers during the COVID-19 period (2020–2022) to pre-COVID-19 levels (2015–2019). Design: Retrospective analysis of aggregated claims data for female cancer diagnostic codes from the Ontario Health Insurance Plan (OHIP). Methods: Linear regression analysis was used to fit pre-COVID-19 (2015–2019) data for each OHIP billing code and extrapolate counterfactual values for the years of 2020–2022. Excess billing rates were calculated as the difference between projected and actual rates for each year. Results: In 2020, OHIP billing prevalence rates for cervical, breast, uterine, and ovarian cancers decreased relative to projected values for that year by −50.7/100k, −13.9/100k, −3.5/100k, and −3.8/100k, respectively. The reverse was observed in 2021 with rate increases of 47.8/100k, 59.1/100k, 2.5/100k, and 3.7/100k, respectively. In 2022, the excesses were further amplified, especially for cervical and breast cancers (111.2/100k and 78.67/100k, respectively). The net excess patient billing rate for 2020–2022 was largely positive for all female cancer types (108.3/100k, 123.7/100k, 5.2/100k, and 1.8/100k, respectively). Analysis of billing incidence rates showed similar trends. Conclusion: The expected female cancer billing rate decreases in 2020 were followed by large increases in 2021 and 2022, resulting in a cumulative excess during the COVID-19 period. Further research is required to assess the nature of these changes.
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessChanges in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan
Background: The initial response to coronavirus disease 2019 (COVID-19) in Ontario included suspension of cancer screening programs and deferral of diagnostic procedures and many treatments. Although the short-term impact of these measures on female cancers is well documented, few studies have assessed the mid- to long-term impacts. Objectives: To compare annual billing prevalence and incidence rates of female cancers during the COVID-19 period (2020–2022) to pre-COVID-19 levels (2015–2019). Design: Retrospective analysis of aggregated claims data for female cancer diagnostic codes from the Ontario Health Insurance Plan (OHIP). Methods: Linear regression analysis was used to fit pre-COVID-19 (2015–2019) data for each OHIP billing code and extrapolate counterfactual values for the years of 2020–2022. Excess billing rates were calculated as the difference between projected and actual rates for each year. Results: In 2020, OHIP billing prevalence rates for cervical, breast, uterine, and ovarian cancers decreased relative to projected values for that year by −50.7/100k, −13.9/100k, −3.5/100k, and −3.8/100k, respectively. The reverse was observed in 2021 with rate increases of 47.8/100k, 59.1/100k, 2.5/100k, and 3.7/100k, respectively. In 2022, the excesses were further amplified, especially for cervical and breast cancers (111.2/100k and 78.67/100k, respectively). The net excess patient billing rate for 2020–2022 was largely positive for all female cancer types (108.3/100k, 123.7/100k, 5.2/100k, and 1.8/100k, respectively). Analysis of billing incidence rates showed similar trends. Conclusion: The expected female cancer billing rate decreases in 2020 were followed by large increases in 2021 and 2022, resulting in a cumulative excess during the COVID-19 period. Further research is required to assess the nature of these changes.
- Top Cited PapersOpen Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (5)
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma
Leung YY, et al. J Gynecol Oncol. 2025 Mar;36:e74. https://doi.org/10.3802/jgo.2025.36.e74
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (5)
Top Cited PapersOpen AccessFOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma
Leung YY, et al. J Gynecol Oncol. 2025 Mar;36:e74. https://doi.org/10.3802/jgo.2025.36.e74
- Open Access
Changes in Female Cancer Diagnostic Billing Rates over the COVID-19 Period in the Ontario Health Insurance Plan
Background and Objectives The initial response to COVID-19 in Ontario included suspension of cancer screening programs and deferral of diagnostic procedures and many treatments. Although the short-term impact of these measures on female cancers is well documented, few studies have assessed the mid- to long-term impacts. We conducted an analysis of Ontario Health Insurance Program (OHIP) claims for female cancer diagnostic codes by comparing annual billing prevalence and incidence rates during the COVID-19 period (2020-2022) to pre-COVID-19 levels (2015-2019). Methods Linear regression analysis was used to fit pre-COVID-19 (2015-2019) data for each OHIP billing code and extrapolate counterfactual values for the years of 2020-2022. Excess billing rates were calculated as the difference between projected and actual rates for each year. Results In 2020, OHIP billing prevalence rates for cervical, breast, uterine and ovarian cancer decreased relative to projected values for that year by -50.7/100k, -13.9/100k, -3.5/100k and -3.8/100k, respectively. The reverse was observed in 2021 with rate increases of 47.8/100k, 59.1/100k, 2.5/100k and 3.7/100k, respectively. In 2022, the excesses were further amplified, especially for cervical and breast cancers (111.2/100k and 78.67/100k, respectively). The net excess patient billing rate for 2020-2022 was largely positive for all female cancers (108.3/100k, 123.7/100k, 5.2/100k, 1.8/100k, respectively). Analysis of billing incidence rates showed similar trends. Conclusion The expected female cancer billing rate decreases in 2020 were followed by large increases in 2021 and 2022, resulting in a cumulative excess during the COVID-19 period. Further research is required to assess the nature of these changes.
Open AccessChanges in Female Cancer Diagnostic Billing Rates over the COVID-19 Period in the Ontario Health Insurance Plan
Background and Objectives The initial response to COVID-19 in Ontario included suspension of cancer screening programs and deferral of diagnostic procedures and many treatments. Although the short-term impact of these measures on female cancers is well documented, few studies have assessed the mid- to long-term impacts. We conducted an analysis of Ontario Health Insurance Program (OHIP) claims for female cancer diagnostic codes by comparing annual billing prevalence and incidence rates during the COVID-19 period (2020-2022) to pre-COVID-19 levels (2015-2019). Methods Linear regression analysis was used to fit pre-COVID-19 (2015-2019) data for each OHIP billing code and extrapolate counterfactual values for the years of 2020-2022. Excess billing rates were calculated as the difference between projected and actual rates for each year. Results In 2020, OHIP billing prevalence rates for cervical, breast, uterine and ovarian cancer decreased relative to projected values for that year by -50.7/100k, -13.9/100k, -3.5/100k and -3.8/100k, respectively. The reverse was observed in 2021 with rate increases of 47.8/100k, 59.1/100k, 2.5/100k and 3.7/100k, respectively. In 2022, the excesses were further amplified, especially for cervical and breast cancers (111.2/100k and 78.67/100k, respectively). The net excess patient billing rate for 2020-2022 was largely positive for all female cancers (108.3/100k, 123.7/100k, 5.2/100k, 1.8/100k, respectively). Analysis of billing incidence rates showed similar trends. Conclusion The expected female cancer billing rate decreases in 2020 were followed by large increases in 2021 and 2022, resulting in a cumulative excess during the COVID-19 period. Further research is required to assess the nature of these changes.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures